Mostra 1 - 16 risultati di 16 ricerca 'Samuel D Rabkin', tempo di risposta: 0,05s Raffina i risultati
  1. 1
    Designing herpes viruses as oncolytics

    Designing herpes viruses as oncolytics di Cole Peters, Samuel D Rabkin

    Pubblicazione 2015-01-01
    Testo
    Articolo
  2. 2
    Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells

    Oncolytic herpes simplex viruses for the treatment of glioma and targeting glioblastoma stem-like cells di Kimia Kardani, Judit Sanchez Gil, Samuel D. Rabkin

    Pubblicazione 2023-05-01
    Testo
    Articolo
  3. 3
    Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma

    Temozolomide antagonizes oncolytic immunovirotherapy in glioblastoma di Dipongkor Saha, Samuel D Rabkin, Robert L Martuza

    Pubblicazione 2020-05-01
    Testo
    Articolo
  4. 4
    Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade

    Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade di Praveen K. Bommareddy, Samuel D. Rabkin, Howard L. Kaufman

    Pubblicazione 2019-04-01
    Testo
    Articolo
  5. 5
    Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma

    Replication-Competent Herpes Simplex Virus Vector G207 and Cisplatin Combination Therapy for Head and Neck Squamous Cell Carcinoma di Ali Chahlavi, Tomoki Todo, Robert L. Martuza, Samuel D. Rabkin

    Pubblicazione 1999-06-01
    Testo
    Articolo
  6. 6
    In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV

    In Situ Cancer Vaccination and Immunovirotherapy Using Oncolytic HSV di Nusrat Jahan, Shanawaz M. Ghouse, Robert L. Martuza, Samuel D. Rabkin

    Pubblicazione 2021-08-01
    Testo
    Articolo
  7. 7
    Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma

    Oncolytic virus immunotherapy induces immunogenic cell death and overcomes STING deficiency in melanoma di Praveen K. Bommareddy, Andrew Zloza, Samuel D. Rabkin, Howard L. Kaufman

    Pubblicazione 2019-07-01
    Testo
    Articolo
  8. 8
    Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival

    Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival di Howard L Kaufman, Dipongkor Saha, Samuel D Rabkin, Robert L Martuza, Praveen K Bommareddy, Hiroaki Wakimoto

    Pubblicazione 2024-04-01
    Testo
    Articolo
  9. 9
    Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy?

    Cytokine-armed oncolytic herpes simplex viruses: a game-changer in cancer immunotherapy? di Howard L Kaufman, Hongbin Wang, Dipongkor Saha, Samuel D Rabkin, Mia Borlongan, Uyen Le, Hans J Nauwynck

    Pubblicazione 2024-05-01
    Testo
    Articolo
  10. 10
    Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer

    Ionizing Radiation Does Not Alter the Antitumor Activity of Herpes Simplex Virus Vector G207 in Subcutaneous Tumor Models of Human and Murine Prostate Cancer di Timothy J. Jorgensen, Sanford Katz, Ellen K. Wittmack, Susan Varghese, Tomoki Todo, Samuel D. Rabkin, Robert L. Martuza

    Pubblicazione 2001-01-01
    Testo
    Articolo
  11. 11
    Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells

    Oncolytic Herpes Simplex Virus and PI3K Inhibitor BKM120 Synergize to Promote Killing of Prostate Cancer Stem-like Cells di Lei Wang, Jianfang Ning, Hiroaki Wakimoto, Shulin Wu, Chin-lee Wu, Melissa R. Humphrey, Samuel D. Rabkin, Robert L. Martuza

    Pubblicazione 2019-06-01
    Testo
    Articolo
  12. 12
    Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models

    Combination of Oncolytic Herpes Simplex Viruses Armed with Angiostatin and IL-12 Enhances Antitumor Efficacy in Human Glioblastoma Models di Wei Zhang, Giulia Fulci, Hiroaki Wakimoto, Tooba A. Cheema, Jason S. Buhrman, Deva S. Jeyaretna, Anat O. Stemmer Rachamimov, Samuel D. Rabkin, Robert L. Martuza

    Pubblicazione 2013-06-01
    Testo
    Articolo
  13. 13
    Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma

    Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma di Jian-Fang Ning, Monica Stanciu, Melissa R. Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L. Martuza, Hiroaki Wakimoto, Samuel D. Rabkin

    Pubblicazione 2019-07-01
    Testo
    Articolo
  14. 14
    Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma

    Characterization and oncolytic virus targeting of FAP-expressing tumor-associated pericytes in glioblastoma di Ming Li, Guoping Li, Juri Kiyokawa, Zain Tirmizi, Leland G. Richardson, Jianfang Ning, Saumya Das, Robert L. Martuza, Anat Stemmer-Rachamimov, Samuel D. Rabkin, Hiroaki Wakimoto

    Pubblicazione 2020-12-01
    Testo
    Articolo
  15. 15
    An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma

    An Aberrant Transcription Factor Network Essential for Wnt Signaling and Stem Cell Maintenance in Glioblastoma di Esther Rheinbay, Mario L. Suvà, Shawn M. Gillespie, Hiroaki Wakimoto, Anoop P. Patel, Mohammad Shahid, Ozgur Oksuz, Samuel D. Rabkin, Robert L. Martuza, Miguel N. Rivera, David N. Louis, Simon Kasif, Andrew S. Chi, Bradley E. Bernstein

    Pubblicazione 2013-05-01
    Testo
    Articolo
  16. 16
    A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS)

    A high-throughput screening and computation platform for identifying synthetic promoters with enhanced cell-state specificity (SPECS) di Ming-Ru Wu, Lior Nissim, Doron Stupp, Erez Pery, Adina Binder-Nissim, Karen Weisinger, Casper Enghuus, Sebastian R. Palacios, Melissa Humphrey, Zhizhuo Zhang, Eva Maria Novoa, Manolis Kellis, Ron Weiss, Samuel D. Rabkin, Yuval Tabach, Timothy K. Lu

    Pubblicazione 2019-06-01
    Testo
    Articolo

Strumenti per la ricerca: